Skip to content

Clinical trials

Tuberculosis, Multidrug-Resistant trials in Peru

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Tuberculosis, Multidrug-Resistant Country / region: Peru Clear all

18 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20071
20081
20093
20111
20141
20152
20161
20191
20203
20221
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed11
Unknown status3
Recruiting2
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Janssen Infectious Diseases BVBA3
Otsuka Pharmaceutical Development & Commercialization, Inc.3
Médecins Sans Frontières, France2
National Institute of Allergy and Infectious Diseases (NIAID)2
Boston University1
Brigham and Women's Hospital1
Foundation for Innovative New Diagnostics, Switzerland1
Harvard Medical School (HMS and HSDM)1
Harvard University Faculty of Medicine1
Partners in Health1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Tuberculosis, Multidrug-Resistant18
Tuberculosis9
Tuberculosis, Pulmonary5
Bacterial Infections2
Extensively Drug-Resistant Tuberculosis2
Gram-Positive Bacterial Infections1
Mycobacterium Infections1

Trials

Showing 76 to 18 of 18. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.